Your browser doesn't support javascript.
loading
Safety and side effect profile of fluoxetine.
Wernicke, Joachim F.
Afiliación
  • Wernicke JF; Lilly Corporate Center, Indianapolis, IN 46285, USA. jfwernicke@lilly.com
Expert Opin Drug Saf ; 3(5): 495-504, 2004 Sep.
Article en En | MEDLINE | ID: mdl-15335304
Fluoxetine was the first selective serotonin re-uptake inhibitor to be widely available for treatment of depression and numerous other neuropsychiatric disorders. Its attributes have been described in numerous scientific papers, and it has been the subject of a considerable volume of lay press. Fluoxetine is generally safe and well-tolerated. Common adverse events reported with the recommended dose of 20 mg/day are referable to the gastrointestinal system and the nervous system. The approved dose range is up to 80 mg/day, and when higher doses are used, adverse events are more common. The long half-life of fluoxetine and its active metabolite essentially preclude a withdrawal phenomenon. It is an inhibitor of cytochrome P450 (CYP) 2D6 and other CYP enzymes, which increases the potential for drug interactions. However, most of these are not clinically important. The purpose of this review is to provide an overview of some of the most important information related to safety and side effects of this drug.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fluoxetina / Inhibidores Selectivos de la Recaptación de Serotonina Tipo de estudio: Etiology_studies Límite: Adolescent / Adult / Child / Female / Humans / Male / Pregnancy Idioma: En Revista: Expert Opin Drug Saf Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2004 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fluoxetina / Inhibidores Selectivos de la Recaptación de Serotonina Tipo de estudio: Etiology_studies Límite: Adolescent / Adult / Child / Female / Humans / Male / Pregnancy Idioma: En Revista: Expert Opin Drug Saf Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2004 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido